Skip to main content
Top
Published in: Journal of General Internal Medicine 6/2008

Open Access 01-06-2008 | Editorial

Prescription Drug Samples: Making Decisions with Imperfect Data

Authors: Jeff Whittle, MD, MPH, Chester B. Good, MD, MPH

Published in: Journal of General Internal Medicine | Issue 6/2008

Login to get access

Excerpt

Americans spend a large amount of money on the purchase of prescription drugs. Under Medicare’s prescription drug benefit (Medicare Part D), Medicare beneficiaries must pay $4,050 out of pocket, not including monthly premiums averaging around $30/month (from Medicare Prescription Drug Plan Finder website), before entering the catastrophic coverage range, after which they are responsible for just 5% of drug costs. Within the infamous doughnut hole between $2,510 and $4,050, beneficiaries will pay 100% of the cost of their prescription drugs. Small wonder, then, that patients, and the physicians caring for them, are grateful for access to free drug samples. These samples can enable therapeutic trials of necessary drugs, avoiding the expense of paying for a full course of a drug that might have to be discarded after the first dose leads to a side effect. A frequent justification provided by physicians is that use of free samples provides access to necessary drugs for patients who could not otherwise afford them.14
Literature
1.
go back to reference Alexander GC, Casalino LP, Meltzer DO. Physician strategies to reduce patients’ out-of-pocket prescription costs. Arch Intern Med. 2005;165:633–6.PubMedCrossRef Alexander GC, Casalino LP, Meltzer DO. Physician strategies to reduce patients’ out-of-pocket prescription costs. Arch Intern Med. 2005;165:633–6.PubMedCrossRef
3.
go back to reference Backer EL, Lebsack JA, Van Tonder RJ, Crabtree BF. The value of pharmaceutical representative visits and medication samples in community-based family practices. J Fam Pract. 2000;49:811–6.PubMed Backer EL, Lebsack JA, Van Tonder RJ, Crabtree BF. The value of pharmaceutical representative visits and medication samples in community-based family practices. J Fam Pract. 2000;49:811–6.PubMed
4.
go back to reference Hall KB, Tett SE, Nissen LM. Perceptions of the influence of prescription medicine samples on prescribing by family physicians. Med Care. 2006;44:383–7.PubMedCrossRef Hall KB, Tett SE, Nissen LM. Perceptions of the influence of prescription medicine samples on prescribing by family physicians. Med Care. 2006;44:383–7.PubMedCrossRef
5.
go back to reference Adair RF, Holmgren LR. Do drug samples influence resident prescribing behavior? A randomized trial. Am J Med. 2005;118:881–4.PubMedCrossRef Adair RF, Holmgren LR. Do drug samples influence resident prescribing behavior? A randomized trial. Am J Med. 2005;118:881–4.PubMedCrossRef
6.
go back to reference Boltri JM, Gordon ER, Vogel RL. Effect of antihypertensive samples on physician prescribing patterns. Fam Med. 2002;34:729–31.PubMed Boltri JM, Gordon ER, Vogel RL. Effect of antihypertensive samples on physician prescribing patterns. Fam Med. 2002;34:729–31.PubMed
7.
go back to reference Hansen LB, Saseen JJ, Westfall JM, Holcomb S, Nuzum DS, Pace WD. Evaluating sample medications in primary care: a practice-based research network study. Joint Comm J Qual & Patient Saf. 2006;32:688–92. Hansen LB, Saseen JJ, Westfall JM, Holcomb S, Nuzum DS, Pace WD. Evaluating sample medications in primary care: a practice-based research network study. Joint Comm J Qual & Patient Saf. 2006;32:688–92.
8.
go back to reference Tjia J, Briesacher B, Soumerai SB, et al. Medicare beneficiaries and free prescription drug samples: A national survey. J Gen Intern Med. 2008; xx: yyy-zzz. Tjia J, Briesacher B, Soumerai SB, et al. Medicare beneficiaries and free prescription drug samples: A national survey. J Gen Intern Med. 2008; xx: yyy-zzz.
9.
go back to reference Cutrona SL, Woolhandler S, Lasser KE, Bor DH, McCormick D, Himmelstein DU. Characteristics of recipients of free prescription drug samples: a nationally representative analysis. Am J Pub Health. 2008;98:284–289.PubMedCrossRef Cutrona SL, Woolhandler S, Lasser KE, Bor DH, McCormick D, Himmelstein DU. Characteristics of recipients of free prescription drug samples: a nationally representative analysis. Am J Pub Health. 2008;98:284–289.PubMedCrossRef
10.
go back to reference Alexander GC, Zhang J, Basu A. Characteristics of patients receiving pharmaceutical samples and association between sample receipt and out-of-pocket prescription costs. Med Care. 2008;46:394–402.PubMedCrossRef Alexander GC, Zhang J, Basu A. Characteristics of patients receiving pharmaceutical samples and association between sample receipt and out-of-pocket prescription costs. Med Care. 2008;46:394–402.PubMedCrossRef
11.
go back to reference Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med. 2003;348:1556–64.PubMedCrossRef Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med. 2003;348:1556–64.PubMedCrossRef
12.
go back to reference Rabin R. Free Drug Samples? Bad Idea, Some Say. The New York Times Company. 2007. Rabin R. Free Drug Samples? Bad Idea, Some Say. The New York Times Company. 2007.
13.
go back to reference Barry P. Medicare Part D: In and Out of the Doughnut Hole. AARP Bulletin Online. 2006. Barry P. Medicare Part D: In and Out of the Doughnut Hole. AARP Bulletin Online. 2006.
Metadata
Title
Prescription Drug Samples: Making Decisions with Imperfect Data
Authors
Jeff Whittle, MD, MPH
Chester B. Good, MD, MPH
Publication date
01-06-2008
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 6/2008
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-008-0642-9

Other articles of this Issue 6/2008

Journal of General Internal Medicine 6/2008 Go to the issue

Reflection

Shoulder Song

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine